174 related articles for article (PubMed ID: 33636481)
1. Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study.
Choe CU; Petersen E; Lezius S; Cheng B; Schulz R; Buhmann C; Pötter-Nerger M; Daum G; Blankenberg S; Gerloff C; Schwedhelm E; Zeller T
Parkinsonism Relat Disord; 2021 Apr; 85():5-10. PubMed ID: 33636481
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
[TBL] [Abstract][Full Text] [Related]
3. Blood Lipid Biomarkers in Early Parkinson's Disease and Parkinson's Disease with Mild Cognitive Impairment.
Deng X; Saffari SE; Ng SYE; Chia N; Tan JY; Choi X; Heng DL; Xu Z; Tay KY; Au WL; Liu N; Ng A; Tan EK; Tan LCS
J Parkinsons Dis; 2022; 12(6):1937-1943. PubMed ID: 35723114
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal and nonlinear relations of dietary and Serum cholesterol in midlife with cognitive decline: results from EMCOA study.
An Y; Zhang X; Wang Y; Wang Y; Liu W; Wang T; Qin Z; Xiao R
Mol Neurodegener; 2019 Dec; 14(1):51. PubMed ID: 31888696
[TBL] [Abstract][Full Text] [Related]
5. Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study.
Wu TT; Zheng YY; Yang YN; Li XM; Ma YT; Xie X
Metab Syndr Relat Disord; 2019 May; 17(4):223-231. PubMed ID: 30720383
[No Abstract] [Full Text] [Related]
6. Lower serum triglyceride levels linked to more severe motor performance in Parkinson's disease.
Zhang M; Chen H; Liu G; Wang X; Wang Z; Feng T; Zhang Y
Neurol Sci; 2022 Sep; 43(9):5343-5353. PubMed ID: 35608738
[TBL] [Abstract][Full Text] [Related]
7. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.
Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM; Chen-Plotkin AS
Mov Disord; 2015 Oct; 30(12):1648-56. PubMed ID: 26207725
[TBL] [Abstract][Full Text] [Related]
8. Decreased Serum Lipid Levels and Ratios Correlate with Low Prevalence of Coronary Heart Disease in Patients with Parkinson's Disease.
Bao M; Hu R; Chen Y; Wang N; Xue H; He J; Jin J; Kong W; Ke G; Xue Q
Clin Lab; 2018 Sep; 64(9):1413-1419. PubMed ID: 30274018
[TBL] [Abstract][Full Text] [Related]
9. The serum lipid profile of Parkinson's disease patients: a study from China.
Guo X; Song W; Chen K; Chen X; Zheng Z; Cao B; Huang R; Zhao B; Wu Y; Shang HF
Int J Neurosci; 2015; 125(11):838-44. PubMed ID: 25340257
[TBL] [Abstract][Full Text] [Related]
10. Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease.
Sleeman I; Lawson RA; Yarnall AJ; Duncan GW; Johnston F; Khoo TK; Burn DJ
J Parkinsons Dis; 2019; 9(2):351-359. PubMed ID: 30909247
[TBL] [Abstract][Full Text] [Related]
11. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
Chen CH; Lee BC; Lin CH
J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
[TBL] [Abstract][Full Text] [Related]
12. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
Santiago JA; Potashkin JA
PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
[TBL] [Abstract][Full Text] [Related]
13. Sex- and age-specific prevalence and risk factors of depressive symptoms in Parkinson's disease.
Niu L; Yao C; Zhang C; Zhou C; Fu Y; Li Y; Yang H; Sun X; Yang J; Zhao P; Yi S; Wang T; Li S; Li J
J Neural Transm (Vienna); 2023 Oct; 130(10):1291-1302. PubMed ID: 37418038
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients.
Liting P; Guoping L; Zhenyue C
Herz; 2015 Mar; 40 Suppl 1():1-7. PubMed ID: 25374385
[TBL] [Abstract][Full Text] [Related]
15. Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study.
Mellor DD; Georgousopoulou EN; D'Cunha NM; Naumovski N; Chrysohoou C; Tousoulis D; Pitsavos C; Panagiotakos DB;
Nutr Metab Cardiovasc Dis; 2020 May; 30(5):788-795. PubMed ID: 32127339
[TBL] [Abstract][Full Text] [Related]
16. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
[TBL] [Abstract][Full Text] [Related]
17. Combined use of apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol before routine clinical lipid measurement in predicting coronary heart disease.
Pan L; Lu G; Chen Z
Coron Artery Dis; 2014 Aug; 25(5):433-8. PubMed ID: 24608795
[TBL] [Abstract][Full Text] [Related]
18. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
[TBL] [Abstract][Full Text] [Related]
19. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
20. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis.
Thompson AG; Talbot K; Turner MR
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):75-81. PubMed ID: 34518331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
